Compare Innovative Industrial Properties Inc (IIPR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

IIPR trades at $51.83, up 1.17% on the day, with a bearish technical signal and mixed earnings history. The stock shows attractive valuation ratios, including a P/E of 11.75 and P/B of 0.83, but revenue declined to $265.96M in 2025. Recent news highlights a $245 million mezzanine loan commitment and a quarterly dividend of $1.90, underscoring its REIT structure and focus on cannabis real estate.

The outlook is cautious due to tenant defaults and dividend sustainability concerns, though the stock offers a high yield and potential regulatory catalysts. Risks include sector volatility and financial performance pressures, while analyst consensus leans hold with a $84.67 price target suggesting upside if operational stability improves.

INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.

The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.